1-18 of 18
Barbara Pro, M.D
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.
Journal: Blood
Blood (2009) 114 (22): 1714.
https://doi.org/10.1182/blood.V114.22.1714.1714
Published: 2009
Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD
Journal: Blood
Blood (2009) 114 (22): 3922.
https://doi.org/10.1182/blood.V114.22.3922.3922
Published: 2009
Journal Articles

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Vince D. Cataldo, M.D., Michael A. Thompson, M.D., PhD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, B. Nebiyou Bekele, PhD, Camilo Jimenez, M.D., William A. Murphy, M.D., Auris O. Huen, Pharm.D., Rebecca B. Arbuckle, Pharm.D., Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Nathan Fowler, M.D., Larry W. Kwak, M.D., Peter W. McLaughlin, M.D., Sattva S. Neelapu, M.D., Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, M.D., Fredrick B. Hagemeister, M.D.
Journal: Blood
Blood (2008) 112 (11): 5297.
https://doi.org/10.1182/blood.V112.11.5297.5297
Published: 2008
Journal Articles

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD, Sattva Neelapu, MD, Michelle Fanale, MD, Maria Rodriguez, MD, Ana Ayala, RN, Barbara Pro, M.D., F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, Larry W. Kwak
Journal: Blood
Blood (2008) 112 (11): 3056.
https://doi.org/10.1182/blood.V112.11.3056.3056
Published: 2008
Journal Articles

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Barbara Pro, M.D., Felipe Samaniego, M.D., Gracy Zachariah, R.N., Cesar A. Nunez, M.D., Yuan Ji, Ph.D., Anas Younes, M.D.
Journal: Blood
Blood (2008) 112 (11): 3048.
https://doi.org/10.1182/blood.V112.11.3048.3048
Published: 2008
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 835.
https://doi.org/10.1182/blood.V112.11.835.835
Published: 2008
Journal Articles

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B 12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, MD, PhD, Barbara Pro, M.D., Lauren Pinter-Brown, MD, Leslie Popplewell, MD, Nancy Barlett, MD, Andrei Shustov, MD, Mary Jo Lechowicz, MD, Kerry J Savage, MD, MSc, Bertrand Coiffier, MD, Eric Jacobsen, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Jasmine Zain, MD, Shannon Wilroy, Molly Patterson, Adam Boyd, Michael E. Saunders, MD, Pablo Cagnoni, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2008) 112 (11): 261.
https://doi.org/10.1182/blood.V112.11.261.261
Published: 2008
Journal Articles

Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

Ali Mazloom, MD, Valerie K Reed, MD, Fernando Cabanillas, MD, Luis Fayad, MD, Barbara Pro, M.D., Puneeth Iyengar, MD, PhD, Peter McLaughlin, MD, Diana L Urbauer, MS, Bouthaina S. Dabaja, MD
Journal: Blood
Blood (2008) 112 (11): 3764.
https://doi.org/10.1182/blood.V112.11.3764.3764
Published: 2008
Journal Articles

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Amin M. Alousi, MD, Chitra Hosing, M.D., Rima M. Saliba, PhD., Rosamar B. Valverde, BSN, Farzaneh Maadani, BS, Martin Korbling, M.D., Grace J. Okoroji, MS, Luis E. Fayad, M.D., Anne M. Stachowiak, BS, William D. Erwin, MS, Paolo Anderlini, M.D., Marcos J. de Lima, M.D., Sergio A. Giralt, M.D., Uday R. Popat, M.D., Partow Kebriaei, M.D., Naoto T. Ueno, M.D., Peter W. McLaughlin, M.D., Barbara Pro, M.D., Michael Wang, M.D., Alma Rodriguez, M.D., Fredrick B. Hagemeister, M.D., Homer A. Macapinlac, M.D., Donald A. Podoloff, M.D., Richard E. Champlin, M.D., Issa F. Khouri, M.D.
Journal: Blood
Blood (2007) 110 (11): 620.
https://doi.org/10.1182/blood.V110.11.620.620
Published: 2007
Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2006) 108 (11): 2749.
https://doi.org/10.1182/blood.V108.11.2749.2749
Published: 2006
Journal Articles

Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

Anas Younes, MD, Luis Y. Fayad, M.D., Andre Goy, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Fredrick Hagemeister, M.D., Maria A. Rodriguez, M.D., Felipe Samaniego, M.D., Larry Kwak, M.D.Ph.D., Sattva Neelapu, M.D., L. Jeffrey Medeiros, M.D., Amanda Wedgwood, R.N., Michelle Fanale, M.D.
Journal: Blood
Blood (2006) 108 (11): 2742.
https://doi.org/10.1182/blood.V108.11.2742.2742
Published: 2006
Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

Gerald S. Falchook, MD, Richard Champlin, M.D., F.B. Hagemeister, M.D., Chitra Hosing, M.D., Larry W. Kwak, M.D., Susan O’Brien, M.D, Maria Alma Rodriguez, M.D., Srdan Verstovsek, M.D., Barbara Pro, M.D.
Journal: Blood
Blood (2006) 108 (11): 2460.
https://doi.org/10.1182/blood.V108.11.2460.2460
Published: 2006
Journal Articles

Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study.

Maria Alma Rodriguez, M.D., Andreas Sarris, M.D., Nam H. Dang, M.D., Luis Fayad, M.D., Andre Goy, M.D., Fredrick Hagemeister, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Felipe Samaniego, M.D., Anas Younes, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2004) 104 (11): 4602.
https://doi.org/10.1182/blood.V104.11.4602.4602
Published: 2004
Journal Articles

Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma.

Anas Younes, M.D., Luis Fayad, M.D., Jorge Romaguera, M.D., Barbara Pro, M.D., Andre Goy, M.D., Nam Dang, M.D., Michael Wang, M.D.
Journal: Blood
Blood (2004) 104 (11): 4646.
https://doi.org/10.1182/blood.V104.11.4646.4646
Published: 2004
Journal Articles

Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Final Results.

Yasuhiro Oki, M.D., Peter McLauhlin, M.D., Barbara Pro, M.D., Frederick H. Hagemeister, M.D., Archie Bleyer, M.D., Evelyn Loyer, M.D., Anas Younes, M.D.
Journal: Blood
Blood (2004) 104 (11): 2494.
https://doi.org/10.1182/blood.V104.11.2494.2494
Published: 2004
Journal Articles

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Yasuhiro Oki, M.D., Barbara Pro, M.D., Ebrahim Delpassand, M. D., Verushka Ballaster, Peter McLaughlin, M.D., Jorge Romaguera, M.D., Michael Wang, M.D., Frederick B. Hagemeister, M.D., Anas Younes, M.D.
Journal: Blood
Blood (2004) 104 (11): 2632.
https://doi.org/10.1182/blood.V104.11.2632.2632
Published: 2004
Journal Articles

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

Anas Younes, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Nam Dang, M.D.
Journal: Blood
Blood (2004) 104 (11): 2638.
https://doi.org/10.1182/blood.V104.11.2638.2638
Published: 2004
Journal Articles

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Luis Fayad, M.D, James Liebmann, M.D, Manuel Modiano, M.D, Gary I. Cohen, M.D, Barbara Pro, M.D, Jorge Romaguera, M.D, Cristina Davite, BSc, Margarita Lymboura, BSc, Silvia Comis, M.D, Bernard L. Laffranchi, M.D
Journal: Blood
Blood (2004) 104 (11): 1324.
https://doi.org/10.1182/blood.V104.11.1324.1324
Published: 2004